Filing Details
- Accession Number:
- 0000947871-23-000336
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-17 16:29:56
- Reporting Period:
- 2023-02-27
- Accepted Time:
- 2023-03-17 16:29:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1739174 | Biomx Inc. | PHGE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1282930 | L Carl Gordon | C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
| 1569590 | Ltd. Gp Israel Orbimed | 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
| 1569821 | Partnership Limited Gp Biofund Israel Orbimed | 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No | |
| 1706399 | Erez Chimovits | C/O Orbimed Israel Gp Ltd. 5 Hahoshlim Street, Building B, 1St Fl. Herzliya Pituach L3 46686 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-27 | 348,000 | $0.25 | 3,161,489 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrants (Right to Buy) | Acquisiton | 2023-02-27 | 1,789,959 | $0.00 | 1,789,959 | $0.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,789,959 | 2023-02-27 | 2033-02-27 | No | 4 | P | Indirect |
Footnotes
- These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants.
- These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.
- Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Billionaire Hedge Funds
